Ultragenyx Shares Fall on Plans to Cut Staff, End Drug Projects

What happened

Ultragenyx said it will cut about 20% of its workforce, ending with roughly 1,000 employees, and discontinue ongoing GTX-102 studies and the UX701 program. It cited failure to meet study goals for UX701 and plans broad cost cuts, with lower research and administrative expenses expected in 2027.

Confirmed

Global impact / market context

Ending two drug programs and reducing staff may lower research and operating costs, but it also narrows the company’s development pipeline, meaning the medicines it is working to bring forward. The effect on future revenue depends partly on whether remaining programs can advance successfully.

Analyst inference

The article reports shares fell 6% to $15.67 in after-hours trading after the announcement, while they were already down 30% this year through the prior close. Third-quarter revenue rose 8%, and the quarterly loss narrowed, alongside the planned cuts.

Confirmed

What to watch

1. Check whether the workforce reduction and real-estate cuts deliver the expected savings, and whether the company provides updates on the timing and costs of carrying them out. Analyst inference
2. Watch for the 2027 expense figures: research and development spending is expected below $350 million, while selling and administrative expenses are expected at $375 million. Proposed
3. Follow updates on the remaining drug-development programs and quarterly revenue, since progress or setbacks could shape whether lower spending supports future growth. Analyst inference

Evidence

• Original source link unavailable